Liaison Technologies, an Atlanta-based provider of cloud-based integration and data management services, said Tuesday that it had completed the milestones required as part of a $30 million investment from Merck’s Global Health Innovation Fund. The investment will fund growth efforts within the healthcare, pharmaceutical and biotechnology industries, the company said.
Liaison Technologies, a global provider of cloud-based integration and data management solutions and services, announced today it has completed the milestones required as part of a $30 million investment from Merck’s Global Health Innovation Fund.
Under terms of the agreement, Liaison completed all milestones ahead of schedule. The investment is being used to fund the growth initiatives of Liaison’s cloud-based integration and data management services within the healthcare, pharmaceutical and biotechnology industries.
Liaison recently announced that its healthcare and life sciences division grew revenues by an average of 40 percent annually in each of the past four years, making it the largest pure-play data integration and management company within the healthcare market.
Liaison’s services help health systems, health information exchanges (HIEs) and pharmaceutical and biotechnology companies securely connect, integrate, aggregate and harmonize large volumes of complex healthcare data from disparate sources to meet interoperability goals. As government mandates and quality care initiatives like meaningful use and Accountable Care Organizations (ACOs) continue to steer the actions of healthcare organizations, it is increasingly important to leverage proven platforms that expedite the sharing of data and provide the valuable information that will lead to better care decisions and improved value-based reimbursement. For life sciences, this approach is also important to expedite clinical trials and connect patients to new therapies that will improve their health.
“This investment in Liaison is a testimony not only to our accomplishments to date but also to our vision of being the leader of integration and data management solutions for the healthcare and life sciences industries,” said Bob Renner, CEO of Liaison Technologies. “It’s an exciting time at Liaison and this investment allows us to focus even more on developing innovative, cloud-based solutions to help pharmaceutical and biotechnology companies increase overall efficiencies and obtain a faster time to market.”
To learn more about Liaison’s healthcare solutions, visit www.liaisonhealthcare.com.
About Liaison Technologies
Liaison Technologies is a global integration, data harmonization and data management company, serving more than 600 customers in the healthcare industry. With customized solutions offered via a cloud-based platform, Liaison helps health systems, HIEs, pharmaceutical and bio-tech companies quickly secure meaningful use from a wide variety of health information. Through connecting healthcare entities and harmonizing complex and disparate data, Liaison assists in the improvement of the care coordination process, leading to increased overall efficiency and faster time-to-market. Headquartered in Atlanta, Liaison has offices in the Netherlands, Finland, Sweden and the United Kingdom. For more information, visit www.liaisonhealthcare.com or call 770-442-4900.
Liaison and the Liaison logo are trademarks of Liaison Technologies, Inc. All other names or product names mentioned in this release are trademarks or registered trademarks of their respective companies.